Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 143

1.

Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).

Vitale MG, Bracarda S, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, Pappagallo GL, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, Gori S, Cartenì G.

Tumori. 2019 Jul;105(4_suppl):3-12. doi: 10.1177/0300891619853392.

PMID:
31264522
2.

Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data.

Ratti M, Hahne JC, Toppo L, Castelli E, Petrelli F, Passalacqua R, Barni S, Tomasello G, Ghidini M.

Ther Adv Med Oncol. 2019 Jun 4;11:1758835919853954. doi: 10.1177/1758835919853954. eCollection 2019. Review.

3.

Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis.

Petrelli F, Tomasello G, Barni S, Varricchio A, Costanzo A, Rampulla V, Cabiddu M, Turati L, Russo A, Seghezzi S, Passalacqua R, Ghidini M.

Surg Oncol. 2019 Jun;29:64-70. doi: 10.1016/j.suronc.2019.03.001. Epub 2019 Mar 6. Review.

PMID:
31196495
4.

Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series.

Bamias A, Hegele A, Medioni J, Castellano D, Doni L, Passalacqua R, Zagouri F, Tzannis K, Hussain S, Ullen A.

Crit Rev Oncol Hematol. 2019 Aug;140:80-87. doi: 10.1016/j.critrevonc.2019.05.006. Epub 2019 May 21. Review.

PMID:
31133463
5.

Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies.

Tomasello G, Ghidini M, Costanzo A, Ghidini A, Russo A, Barni S, Passalacqua R, Petrelli F.

J Gastrointest Oncol. 2019 Apr;10(2):259-269. doi: 10.21037/jgo.2018.12.08.

6.

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F.

Cancers (Basel). 2019 Apr 5;11(4). pii: E484. doi: 10.3390/cancers11040484. Review.

7.

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).

Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group.

Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13.

PMID:
30867244
8.

Epidemiological, clinical and pathological characteristics of gastric neoplasms in the province of Cremona: the experience of the first population-based specialized gastric cancer registry in Italy.

Donida BM, Tomasello G, Ghidini M, Buffoli F, Grassi M, Liguigli W, Maglietta G, Pergola L, Ratti M, Sabadini G, Toppo L, Ungari M, Passalacqua R.

BMC Cancer. 2019 Mar 8;19(1):212. doi: 10.1186/s12885-019-5366-1.

9.

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).

Aapro M, Ruiz-Borrego M, Hegg R, Kukielka-Budny B, Morales S, Cinieri S, Freitas-Junior R, Garcia-Estevez L, Szombara E, Borges GS, Passalacqua R, Hervieu H, Groc M, Villanova G.

Breast. 2019 Jun;45:7-14. doi: 10.1016/j.breast.2019.01.009. Epub 2019 Jan 28.

PMID:
30802822
10.

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.

N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

PMID:
30786186
11.

Biliary tract cancer: current challenges and future prospects.

Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F.

Cancer Manag Res. 2018 Dec 28;11:379-388. doi: 10.2147/CMAR.S157156. eCollection 2019. Review.

12.

Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.

Petrelli F, Ghidini M, Barni S, Sgroi G, Passalacqua R, Tomasello G.

Gastric Cancer. 2019 Mar;22(2):245-254. doi: 10.1007/s10120-018-0901-3. Epub 2018 Nov 27.

PMID:
30483986
13.

Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.

Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N.

Cell Mol Life Sci. 2018 Nov;75(22):4151-4162. doi: 10.1007/s00018-018-2906-9. Epub 2018 Sep 1. Review.

14.

MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Ghidini M, Hahne JC, Frizziero M, Tomasello G, Trevisani F, Lampis A, Passalacqua R, Valeri N.

Target Oncol. 2018 Aug;13(4):423-436. doi: 10.1007/s11523-018-0580-3.

PMID:
30006826
15.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.

PMID:
29956884
16.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
17.

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R.

Drugs R D. 2018 Jun;18(2):163. doi: 10.1007/s40268-018-0234-z.

18.

Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis.

Petrelli F, Maltese M, Tomasello G, Conti B, Borgonovo K, Cabiddu M, Ghilardi M, Ghidini M, Passalacqua R, Barni S, Brighenti M.

Clin Lung Cancer. 2018 Jul;19(4):315-322. doi: 10.1016/j.cllc.2018.02.006. Epub 2018 Feb 21.

PMID:
29530732
19.

Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.

Tomasello G, Barni S, Turati L, Ghidini M, Pezzica E, Passalacqua R, Petrelli F.

Clin Colorectal Cancer. 2018 Jun;17(2):97-103. doi: 10.1016/j.clcc.2018.02.001. Epub 2018 Feb 15.

PMID:
29519711
20.

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.

Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM, Panni S, Ratti M, Lazzarelli S, Gerevini F, Colombi C, Panni A, Rovatti M, Treccani L, Martinotti M, Passalacqua R.

Oncotarget. 2017 Dec 4;8(67):111795-111806. doi: 10.18632/oncotarget.22909. eCollection 2017 Dec 19.

Supplemental Content

Loading ...
Support Center